$コーバス ファーマシューティカルズ(CRVS.US)$Corvus Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Advisors LLC(11.1%),OrbiMed Capital GP V LLC(11.1%)
$コーバス ファーマシューティカルズ(CRVS.US)$Richard A Miller, Director, President and CEO, on May 06, 2024, executed a purchase for 577,634 shares in Corvus Pharmaceuticals (CRVS) for $1,000,000. Following the Form 4 filing with the SEC, Miller has control over a total of 2,067,753 shares of the company, with 577,634 shares held directly and 1,490,119 controlled indirectly.
$コーバス ファーマシューティカルズ(CRVS.US)$Reuters· 2 mins Corvus Pharmaceuticals - Issue and Sell to Investors in Registered Direct Offering Aggregate of 13.5 Mln Shares of Common Stock, Among Others
$コーバス ファーマシューティカルズ(CRVS.US)$Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
$コーバス ファーマシューティカルズ(CRVS.US)$But its nice to see when i do agree! Even lower by a buck 7 would still be killer gains! LMAO. ((((((. Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 to $7. )))))
$コーバス ファーマシューティカルズ(CRVS.US)$Corvus Pharmaceuticals (CRVS) said Tuesday it expects to start a phase 1 study of soquelitinib in patients with moderate to severe atopic dermatitis in Q2. Corvus expects to enroll 64 patients who have previously failed at least one therapy and compare four different doses of the drug with placebo for safety and disease severity in the 28-day trial. An initial readout of the trial is possible before the year's end, according to the company.
コーバス ファーマシューティカルズに関するコメント
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus expects to enroll 64 patients who have previously failed at least one therapy and compare four different doses of the drug with placebo for safety and disease severity in the 28-day trial.
An initial readout of the trial is possible before the year's end, according to the company.
まだコメントはありません